Substudy 1 for Stomach Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Research Site, Elche(Alicante), SpainStomach CancerMEDI5752 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests new treatments for gastric/GEJ cancer to see if they're safe, effective and tolerable.

Eligible Conditions
  • Stomach Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years

Year 2
ORR (per RECIST 1.1 as assessed by Investigator)
OS
PFS per RECIST 1.1 as assessed by the Investigator
PFS6 (per RECIST 1.1 as assessed by Investigator)
other safety related endpoints

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Substudy 1
1 of 2
Substudy 2
1 of 2

Experimental Treatment

80 Total Participants · 2 Treatment Groups

Primary Treatment: Substudy 1 · No Placebo Group · Phase 2

Substudy 1Experimental Group · 3 Interventions: MEDI5752, XELOX, FOLFOX · Intervention Types: Drug, Drug, Drug
Substudy 2Experimental Group · 3 Interventions: XELOX, FOLFOX, AZD2936 · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XELOX
2018
Completed Phase 3
~340
FOLFOX
2009
Completed Phase 3
~3760

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 2 years

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,019 Previous Clinical Trials
240,381,068 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 3 months.

Frequently Asked Questions

To what extent is Substudy 2 hazardous to individuals?

"Based on the existing evidence, Substudy 2 received a score of 2. This is because it has progressed to Phase 2 and there is some data that suggests safety but not efficacy." - Anonymous Online Contributor

Unverified Answer

Are there any available slots for the trial yet?

"As evidenced on clinicaltrials.gov, this particular trial is presently onboarding participants and was last updated March 15th of 2023 - with initial posting having taken place January 16th of the same year." - Anonymous Online Contributor

Unverified Answer

How many healthcare facilities are currently participating in this experiment?

"At present, 26 medical sites are accepting participants for this clinical trial. These locations include Santander, Taoyuan City and Barcelona among many others; therefore it is highly beneficial to select the closest centre to reduce travel demands if one chooses to join the study." - Anonymous Online Contributor

Unverified Answer

How many subjects are involved with this research endeavor?

"Affirmative. According to clinicaltrials.gov, this study is actively seeking participants with the first posting date of January 16th 2023 and last updated on March 15th 2023. 80 people are needed from 26 different medical centres for completion of the trial." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.